From: Zika vaccines and therapeutics: landscape analysis and challenges ahead
Study | No. of drugs screened | Compounds identified with anti-Zika activity | Remarks |
---|---|---|---|
Barrows et al. [54] | 774 FDA-approved agents | Clofazimine, Digoxin, Gemcitabine, Ivermectin, Mefloquine, Mercaptopurine hydrate, Mycophenolic acid, Fingolimod, Mycophenolate mofetil, Dactinomycin, Bortezomib, Methoxsalen (Xanthotoxin), Azathioprine, Thioguanine, Auranofin, Sertraline, Pyrimethamine, Daptomycin, Palonosetron, Deferasirox, Micafungin, Sorafenib tosylate, Cyclosporine A, Mebendazole | • Mycophenolic acid (MPA), Ivermectin, Daptomycin, Mefloquine, Palonosetron identified as having higher potency • Daptomycin, Mefloquine, and Palonosetron are pregnancy category B drugs |
Xu et al. [58] | 6000 compounds, > 2000 FDA-approved agents | Niclosamide, Emricasan, 10 structurally unrelated inhibitors of CDK | • Emricasan is an inhibitor of caspase-3 activity but uncertain if a capase-3 inhibitor with anti-inflammatory properties impacts development of unborn fetus |